Stay updated on Safety & Efficacy of FG-3019 in IPF Clinical Trial
Sign up to get notified when there's something new on the Safety & Efficacy of FG-3019 in IPF Clinical Trial page.

Latest updates to the Safety & Efficacy of FG-3019 in IPF Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedRemoved the Interstitial lung disease 2 entry and the Genetic and Rare Diseases Information Center resources from the page navigation.SummaryDifference0.1%

- Check22 days agoChange DetectedRevision: v3.5.0 updated, replacing the previous v3.4.3.SummaryDifference0.0%

- Check36 days agoChange Detected- Revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. The page content and study details appear unchanged.SummaryDifference0.0%

- Check64 days agoChange DetectedThe page's revision label was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check79 days agoChange DetectedSponsor information updated: FibroGen was replaced by Kyntra Bio as the sponsor/responsible party in the study record.SummaryDifference0.1%

Stay in the know with updates to Safety & Efficacy of FG-3019 in IPF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety & Efficacy of FG-3019 in IPF Clinical Trial page.